Written by: Bryan J. Brinda, PharmD
Download Here

This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. Optimal patient identification, dosing, and follow-up are essential to help patients benefit fully while taking this medication. Continue reading Gilteritinib (XOSPATA) for Relapsed/Refractory Acute Myeloid Leukemia (AML)

Read More

Written by: Michelle Phillips, PharmD
Download Here

Summary of dosing, administration, and clinical experience to ease the dispensing and management of niraparib.
Continue reading Niraparib dose adjustment based on weight and platelet counts

Read More

Written by: Jody Agena, PharmD
Download Here

Understand how to effectively manage adverse effects of Regorafenib treatment in Hepatocellular Carcinoma.
Continue reading Regorafenib in the treatment of Hepatocellular Carcinoma

Read More

Written by: Jonas Congelli, RPh Hematology Oncology Associates of CNY
Download Here

Preventative use of 10‐20% urea cream has been shown to reduce the severity and time to developing hand‐foot syndrome (HFS).Patients started on medications known to cause HFS will be educated on the importance of using 10‐20% urea cream to prevent HFS. Continue reading Drug Induced Hand‐Foot Syndrome

Read More